Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Second Quarter and Interim results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230523:nRSW2677Aa&default-theme=true

RNS Number : 2677A  Benchmark Holdings PLC  23 May 2023

Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014 and
Article 7 of the UK version of EU Regulation 596/2014 which forms part
of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

23 May 2023

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

 

Second Quarter and Interim results for the six months ended 31 March 2023

 

Strong Q2 and H1 results continuing track record of quarterly growth and
strategic delivery

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, announces its
unaudited interim results for the six months ended 31 March 2023 (the "Period"
or "H1 FY23"). The Company also announces its unaudited results for the three
months ended 31 March 2023 ("Q2 FY23") in compliance with the terms of its
unsecured Green bond.

Financial highlights

·    Excellent H1 FY23 results driven by good performance in all business
areas:

o  25% growth in revenues to £98.9m (H1 FY22: £79.2m)

o  39% increase in Adj. EBITDA to £22.1m (H1 FY22: £15.9m)

o  47% increase in Adj. EBITDA excluding fair value ("FV") movement in
biological assets to £21.8m (H1 FY22: £14.8m):

§ Adj. EBITDA margin excluding FV movement in biological assets increased to
22% (H1 FY22: 19%)

o  193% increase in Adj. Operating profit excluding FV movement in biological
assets to £11.4m (H1 FY22: £3.9m)

o  Further reduction in loss before tax

o  Operating cash inflow £9.5m (H1 FY22: cash inflow of £2.0m)

·    Strong Q2 FY23 performance building on track record of continuous
quarterly improvement:

o  Revenues +13% to £44.4m (Q2 FY22: £39.2m)

o  Adj. EBITDA +32% to £11.1m (Q2 FY22: £8.4m); Adj. EBITDA margin of 25%
in line with medium term target set in May 2022

o  Adj. EBITDA excluding FV movement in biological assets +32% to £9.7m (Q2
FY22: £7.3m); Adj. EBITDA margin excluding FV movement in biological assets
of 22% (Q2 2022: 19%)

o  Adj. Operating profit excluding fair value movement in biological assets
+244% to £4.5m (Q2 FY22: £1.3m)

·    Net debt (excluding lease liabilities) continues to reduce to £44.5m
(30 September 2022: £47.5m; 31 March 2022: £50.6m):

o  Cash of £41.9m and liquidity (cash and available facility) of £53.9m at
22 May 2023

Business Area highlights

·    Genetics - strong performance in core salmon business and strategic
progress in growth areas:

o  H1 FY23 Revenues +30% driven by higher salmon sales from Norway and
Iceland; 181m salmon eggs sold (H1 FY22: 134m)

o  Continued commercial progress in Chile with new customer wins

o  Obtained "disease free compartment status" from the Chilean regulator, an
important biosecurity endorsement which will enable the Company to export
salmon eggs from Chile

o  Completed configuration at Salten, Norway facility to reach 150m salmon
eggs production capacity from FY24 (currently 140m), ahead of plan

o  Total salmon egg capacity now 400m eggs, comprising 150m in Norway, 200m
in Iceland and 50m in Chile

o  Strengthened scientific team to progress positioning on new technologies;
enhanced genotyping capabilities

·    Advanced Nutrition - strong performance despite soft shrimp markets
demonstrates success of commercial focus and agile operation:

o  Marginally lower revenues in Q2 FY23 albeit 8% higher revenues for H1 FY23
as a whole

o  Strong performance in marine fish species which represent c.25% of
revenues

o  Uplift in shrimp market expected as inventory levels normalise along the
global supply chain and consumer confidence improves

·    Health - strong result from combined sea lice product portfolio and
integrated commercial team:

o  Continuing adoption of Ectosan® Vet and CleanTreat® supported by
excellent efficacy resulting in H1 FY23 sales of £12.9m, up 50% on last year

o  Progress on development of streamlined integrated CleanTreat®
infrastructure with partners MMC and Salt Ship Design

o  Strong sales of Salmosan® Vet driven by success of new marketing label

Current trading and outlook

·    On track to deliver strong growth for the year in line with market
expectations:

o  Good visibility of salmon egg sales from Norway and Iceland

o  Market conditions in shrimp are expected to remain unchanged in the short
term; well positioned for resilience and market share wins. Positive backdrop
in the Mediterranean marine fish market

o  Expect Q3 FY23 sales from Ectosan® Vet and CleanTreat® to reflect low
sea lice treatment season, thereafter increasing in Q4 FY23

·    Update on Oslo Børs uplisting:

o  Consultation with shareholders regarding a potential delisting from AIM
and uplisting to Oslo Børs completed

o  Plan to maintain a dual listing on Euronext Growth Oslo and on AIM for the
foreseeable future. Uplisting to Oslo Børs will be reviewed as part of
ongoing strategy to enhance Group positioning and share performance

 £m                                                                                         % CER               Q2 FY22  % CER

                                                                        H1 FY23   H1 FY22   H1 FY23   Q2 FY23            Q2 FY23
 Revenue                                                                98.9      79.2      +19%      44.4      39.2     +9%

                                                                        +25%                          +13%
 Adjusted
 Adjusted EBITDA(1)                                                     22.1      15.9      +36%      11.1      8.4      +28%

                                                                        +39%                          +32%
 Adj. EBITDA excluding biological asset fair value movements            21.8      14.8      +42%      9.7       7.3      +28%

                                                                        +47%                          +32%
 Adjusted Operating profit(2)                                           11.7      4.9       +130%     5.9       2.4      +134%

                                                                        +138%                         +145%
 Adj. Operating profit excluding biological asset fair value movements  11.4      3.9       180%      4.5       1.3      220%

                                                                        +193%                         +244%
 Statutory
 Operating profit/(loss)                                                0.3       (2.2)     +97%      0.4       (0.7)    +122%

                                                                        +114%                         +159%
 Loss before tax                                                        (1.9)     (5.1)     +65%      (2.0)     (1.5)    -56%

                                                                        +63%                          -38%
 Basic loss per share (p)                                               (0.57)    (1.32)              (0.40)    (0.54)
 Net debt(3)                                                            (66.3)    (81.4)              (66.3)    (81.4)
 Net debt(3) excluding lease liabilities                                (44.5)    (50.6)              (44.5)    (50.6)

 

Business Area summary

 £m                                                                                  %CER*                              % CER*

                                                                 H1 FY23   H1 FY22   H1 FY23   Q2 FY23   Q2 FY22   Q2 FY23
 Revenue
 Advanced Nutrition                                              45.3      42.0      -4%       22.6      23.0      -10%

                                                                 +8%                           -1%
 Genetics                                                        34.5      26.6      +31%      13.0      11.4      +16%

                                                                 +30%                          +14%
 Health                                                          19.1      10.7      +79%      8.7       4.9       +78%

                                                                 +78%                          +77%
 Adjusted EBITDA(1)
 Advanced Nutrition                                              11.5      11.5      -9%       6.2       7.2       -21%

                                                                 0%                            -14%
 Genetics                                                        6.0       5.7       +16%      3.4       2.4       +51%

                                                                 5%                            +41%
 -       Net of fair value movements in biological assets        5.7       4.7       +32%      2.0       1.3       +67%

                                                                 +22%                          +52%
 Health                                                          6.6       0.1       +6,957%   2.6       (0.5)     +663%

                                                                 +7,034%                       +669%

 

 

*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

 

Trond Williksen, CEO, commented:

"Benchmark had an excellent first half, delivering double digit growth. We
continue to focus on achieving profitability and cash generation whilst making
good progress towards our medium-term objectives; we remain on track to
deliver strong growth for the year in line with market expectations.

 

"Our fundamentals are strong and we have significant opportunities to continue
building our track record of consistent growth. Aquaculture is a growth
industry, supported by robust megatrends. Benchmark is well positioned to play
an important role in helping the aquaculture industry deliver sustainable
growth and meet the needs of a rising population."

 

Presentation for analysts and institutional investors at 08.00 UK time (09.00
CET)

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time.

 

The presentation will be held in person at Pareto Securities offices in Oslo
at Dronning Mauds gate 3, N‑0250 Oslo, Norway. If you would like to attend
in person, please contact Thea Naess at thea.naess@paretosec.com.

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230523_3
(https://protect-eu.mimecast.com/s/QkqoCwjMxfNEly6c81Srh?domain=channel.royalcast.com)
(https://protect-eu.mimecast.com/s/QkqoCwjMxfNEly6c81Srh?domain=channel.royalcast.com)

 

A copy of the presentation can be found on the Company's website
https://www.benchmarkplc.com/investors/reports-presentations/

 

Equity Development webcast at 12.00 UK time

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers on
the day at 12.00 UK time. The webcast is open to all existing and potential
shareholders.

 

To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)

2qresults-presentation-23may2023
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)

 

A recording of the presentation will be available after the event on the
Equity Development website
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings) .
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings)

 

 

Enquiries

 

 For further information, please contact:
 Benchmark Holdings plc                            benchmark@mhpgroup.com (mailto:benchmark@mphgroup.com)

 Trond Williksen, CEO

 Septima Maguire, CFO

 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                          Tel:  020 7260 1000

 Freddie Barnfield, Duncan Monteith, Sher Shah

 MHP                                               Tel:  020 3128 899

 Katie Hunt, Reg Hoare, Veronica                   benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
 Farah

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth, animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses the major aquaculture species in all the
major aquaculture regions around the world. Find out more at
www.benchmarkplc.com (http://www.benchmarkplc.com)

 

Management Report

 

Benchmark delivered an excellent performance in the first half of the year
continuing to build on its track record of consistent quarterly increase in
revenues and underlying profitability. Revenues were up 25% (19% at constant
currency) reaching £98.9m, and Adjusted EBITDA excluding fair value movements
from biological assets at £21.8m was up 47% (42% at constant currency)
against H1 FY22, translating into an Adjusted EBITDA margin excluding fair
value movements of 22% (H1 FY22: 19%). Adjusted EBITDA increased by 39% (36%
at constant currency) in the six-month period. The increase in Adjusted EBITDA
excluding fair value movements from biological assets derives primarily from
higher revenues, supported by ongoing cost control and operational leverage.

 

Higher revenues were reported across all business areas with Genetics revenues
increasing by 30%, Advanced Nutrition 8% and Health 78%.  In Health and
Genetics, the impact from foreign currencies was not material, with revenue
growth at constant currency broadly in line with actual revenue growth.
Advanced Nutrition sales were aided by forex tailwinds, and revenue fell
slightly (-4%) in constant currency terms.  Operating costs in H1 FY23 were
£24.0m, a 21% increase from the prior year. The increase reflects higher
activity levels and inflationary pressure.  R&D expenses at £3.0m, were
7% below H1 FY22 and total R&D investment including capitalised
development costs was £3.2m, 30% below the prior year (H1 FY22: £4.6m).

 

Depreciation and amortisation were marginally above the prior year at £19.1m
(H1 FY22: £18.9m). Together with the increase in EBITDA, this led to an
improvement at Operating Profit level to £0.3m (H1 FY22: -£2.2m loss).
Adjusted Operating Profit excluding fair value movements from biological
assets increased by 193% to £11.4m. Taking into consideration conditions in
the end markets, performance was strong across all business areas.

 

Net finance costs for H1 FY23 were £2.2m (H1 FY22: £3.0m).  The reduction
arises due to a credit of £2.7m arising in H1 relating to the ineffective
portion of the movement in the fair value of derivative financial instruments,
offset by higher forex losses in the period.

 

Loss before tax in H1 FY23 was £1.9m (H1 FY22: £5.1m). This included the
impact of significant exceptional costs in the period of £2.7m, largely
incurred in legal and professional costs in relation to the preparations for
listing the Group on the Oslo Børs. The figure contrasted with a £0.9m net
credit in H1 FY22 which included a credit of £1.2m for additional contingent
consideration received from disposals in previous years.

 

Total tax charge in H1 FY23 was £1.5m (H1 FY22: £3.6m) reflecting a change
in the mix in the territories in which the profits have been made, with losses
available to shelter profits in some territories.  Loss after tax was £3.4m
(H1 FY22: £8.8m loss).

 

The Group reported a net operating cash inflow of £9.5m after an increase in
working capital of £4.2m (H1 FY22: £13.5m) and tax payments of £4.1m (H1
FY22: £3.0m). The increase in working capital is somewhat seasonal, but the
much lower increase year on year, in the context of increased activity,
results from our strong focus on managing our working capital closely towards
our goal of achieving positive cash generation.

 

Net cash outflow from investing activities was £11.5m (H1 FY22: £6.6m) of
which £8.0m related to the acquisition of the remaining minority stake in
Benchmark Genetics Iceland completed in February 2023.  PPE capex was £3.3m
(H1 FY22: £5.1m).

 

Net cash inflow from financing activities of £6.8m (H1 FY22: £10.7m),
includes an equity raise of (net) £13.0m, net proceeds from debt refinancing
of £4.2m, and £4.7m of lease payments (H1 FY22: £4.8m). Interest charges in
the period were £4.0m (H1 FY22: £3.8m), as the higher cost of borrowing
offset the lower level of borrowings outstanding in the period. Our cash
position at the end of the period was £38.6m (H1 FY22: £46.3m), and net debt
including lease liabilities was £66.3m (H1 FY22: £81.4m).

 

Advanced Nutrition

 

Advanced Nutrition delivered a strong result despite soft shrimp markets in
the first half of the year demonstrating the success of a renewed commercial
focus and agile operation. Revenues for the first half were up 8% at £45.3m
while Adjusted EBITDA was flat against the same period in the previous year at
£11.5m.

 

Softness in the shrimp markets resulted from subdued demand from key import
markets, inventory levels across the supply chain and higher input costs,
primarily in South East Asia, while Ecuador was more robust.  We expect an
uplift in shrimp production as consumer confidence picks up and inventory
levels normalise. Conditions in the marine fish sector were positive partially
offsetting softness in the shrimp market.

 

In transactional currency, by product area, Artemia sales were up 3% and
Health sales were up by 22% while Diets saw a 14% decrease.  On the same
basis by region, Asia Pacific and South East Asia were most affected by
conditions in the shrimp market leading to a reduction in sales of 13% and 19%
respectively. Conversely, the Americas reported growth of 8% while sales in
Europe increased 6%.

 

With a leading position in the market, deep customer relations, operational
agility and commercial focus our Advanced Nutrition business is well placed to
mitigate the temporary weakness and take every opportunity to strengthen our
position in the market.

 

 

Genetics

Genetics delivered strong performance in the first half of the year with
revenues of £34.5m, 30% above the prior year (H1 FY22: £26.6m) driven by
higher salmon egg sales and harvest revenues. Adjusted EBITDA for H1 FY23
excluding fair value movements of biological assets was £5.7m, 22% ahead of
the prior year (H1 FY22: £4.7m). Including fair value movements Adjusted
EBITDA for the first half was £6.0m, 5% ahead of the same period last year.

Revenues from salmon eggs increased by 45% driven by Norway and Iceland, while
harvest revenues grew by 9%.  We made commercial progress in Chile with new
customer wins.  In addition, we obtained "disease free compartment status"
from the Chilean regulator, Senapesca. This is an important biosecurity
endorsement which will enable the Company to export salmon eggs from Chile
thereby opening new avenues to utilise our installed capacity.

 

In Q2 we completed the configuration of the Salten facility, to reach 150m
salmon egg capacity (currently 140m eggs) which will be in place from FY24
onwards. This marks the end of an investment journey where the Company has
increased its total salmon egg capacity to 400m eggs, comprising 150m in
Salten, Norway, 200m in Iceland and 50m in Chile.

In shrimp we continued our efforts to enhance and tailor genetic traits to
local markets and trials in local markets are underway.  We have decreased
the intensity of our commercial efforts while the trials are ongoing. Shrimp
sales were £0.7m in the period (H1 FY22: £0.8m).

 

Innovation is a core component of our Genetics strategy and we continue to
strengthen our capability in the team. We have also enhanced our capacity for
genotyping, reducing the costs for our own programmes and enabling us to offer
genotyping as part of our offering in genetics services.

 

During the period the Company acquired the remaining 10.52% minority interest
in its subsidiary Benchmark Genetics Iceland ensuring Benchmark receives the
full benefit from its successful salmon genetics business in Iceland.
Benchmark Genetics Iceland represents c.50% of the Group's 400m salmon egg
capacity.

 

Health

 

Revenues in H1 FY23 increased to £19.1m (H1 FY22: £10.7m) with higher
sales from both Ectosan® Vet and CleanTreat® and Salmosan® Vet.  Ectosan®
Vet and CleanTreat® sales were £12.9m (H1 FY22: £8.6m) of which £4.5m (H1
FY22: £2.2m) related to recharging of vessel and fuel costs. There is growing
adoption of our highly efficacious sea lice solution and we continue to work
with our partners MMC and Salt Ship Design to develop a streamlined
infrastructure for CleanTreat® which will further facilitate adoption in the
market.

 

Salmosan® Vet sales were £6.2m, 192% ahead of the prior year supported by
the success of a new marketing label.

 

Adjusted EBITDA for the business area was £6.6m (H1 FY22: £0.1m).

 

Q2 FY23 commentary

 

The Group reported revenue of £44.4m, 13% above prior year of £39.2m. This
was driven by revenue growth in Health and Genetics which reported revenue
+77% and +14% higher than Q2 FY22 respectively. Revenues in Advanced Nutrition
were marginally down -1% driven by low current demand in the shrimp markets as
mentioned above.

 

Adjusted EBITDA excluding fair value uplift from biological assets was £9.7m,
32% ahead of the prior year and 28% higher on a constant currency basis (Q2
FY22: £7.3m), reflecting higher revenues, operational leverage and good cost
control. By business area, Health was up more than sixfold, Genetics was up
52% while Advanced Nutrition reported a decrease in Adjusted EBITDA of 14%,
despite forex tailwinds mitigating the reduction.

 

Operating costs of £12.3m were 23% above last year (Q2 FY22: £10.0m) driven
by increased activity and inflationary pressure. R&D expenses of £1.4m
were 10% below the prior year (Q2 FY22: £1.6m) and represented 3% of Group
revenues (Q2 FY22: 4%).  Depreciation and amortisation was £9.0m (Q2 FY22:
£10.0m), leading to a Group operating profit of £0.4m (Q2 FY22: £0.7m
loss).

 

Net finance costs of £2.4m for the quarter were £1.6m higher than the same
period last year (Q2 FY22: £0.8m), mainly due to forex losses of £0.7m (Q3
FY22: gain of £0.6m) in the period.

 

The tax charge of £0.7m (Q2 FY22: £2.2m) reflects a change in the mix of
territories in which taxable profits were made, leading loss after tax for the
quarter at £2.7m (Q2 FY22: loss of £3.7m).

 

 

Update on Oslo Børs listing

 

As previously announced, the Company conducted a consultation with
shareholders regarding a potential delisting from AIM and uplisting to the
Oslo Børs. Based on the feedback received the Board has decided to maintain
its current listings on Euronext Growth Oslo and on AIM for the foreseeable
future.

The Board continues to believe that in the medium term the company could
benefit from uplisting to the Oslo Børs as the leading venue for seafood and
aquaculture companies. An uplisting will be reviewed as part of the Group's
ongoing strategy to enhance the Group's positioning and shareholder value.

 

Outlook and current trading

 

The Group had an excellent first half, delivering 25% growth in revenues and
trading in line with market expectations. We continued to focus on achieving
profitability and cash generation whilst making good progress towards our
medium-term objectives.

 

The Group communicated its medium term (3-5 year) financial objectives in May
2022 and since then has reported significant progress as shown in the table
below:

 

                                 Medium term objective  FY21   FY22  H123
 Revenue Growth per annum        15-18%                 18%    27%   25%
 Adj. EBITDA Margin              25-30%                 16%    20%   22%

                                 (period end)
 Cashflow conversion ratio(1)    70-80%                 30%    35%   43%
 Free cashflow as % of sales(2)  10-15%                 (17%)  (8%)  1%

 

1.        Cash generated from operations after working capital and
taxes as percentage of Adj. EBITDA

2.        Free cash flow: Net cash from operating activities less capex
and lease payments (excluding cash interest)

 

Looking forward to the second half of the year there is good visibility of
salmon egg sales in Genetics and we will continue to progress our growth
vectors of salmon in Chile and shrimp genetics, which will be key areas of
focus in the coming periods.  In Advanced Nutrition we expect conditions in
the shrimp market to remain unchanged in the short term and while this poses a
challenge to growth, we are confident that we have a leading and dynamic
organisation capable of mitigating the impact from market conditions whilst
taking advantage to increase our market share where possible. In Health, we
expect Q3 sales to reflect the seasonally low sea lice treatment season,
thereafter increasing in Q4.

 

Our fundamentals are strong and we have significant opportunities to continue
building our track record of consistent growth. Since completing the Group's
restructuring in 2020 we have delivered a 62% increase in revenue and 117%
increase in Adj. EBITDA, whilst steadily reducing net debt. Aquaculture is a
growth industry, supported by robust megatrends. As a leading aquaculture
biotechnology company, Benchmark is well positioned to play an important role
in helping the aquaculture industry deliver sustainable growth and meet the
needs of a rising population.

Benchmark Holdings plc

 

Consolidated Income Statement for the period ended 31 March 2023

 

 

 

 All figures in £000's                                                Notes  Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Revenue                                                              4      44,367        39,233        98,862        79,247        158,277
 Cost of sales                                                               (19,549)      (19,210)      (49,817)      (39,725)      (75,149)
 Gross profit                                                                24,818        20,023        49,045        39,522        83,128
 Research and development costs                                              (1,435)       (1,590)       (2,998)       (3,237)       (6,691)
 Other operating costs                                                       (12,290)      (9,984)       (24,043)      (19,907)      (44,661)
 Share of (loss)/profit of equity-accounted investees, net of tax            -             (24)          56            (528)         (595)
 Adjusted EBITDA²                                                            11,093        8,425         22,060        15,850        31,181
 Exceptional - restructuring, disposal and acquisition related items  5      (1,716)       908           (2,688)       908           16
 EBITDA¹                                                                     9,377         9,333         19,372        16,758        31,197
 Depreciation and impairment                                                 (4,551)       (5,557)       (9,166)       (10,052)      (19,897)
 Amortisation and impairment                                                 (4,410)       (4,484)       (9,912)       (8,872)       (19,161)
 Operating profit/(loss)                                                     416           (708)         294           (2,166)       (7,861)
 Finance cost                                                                (3,223)       (2,684)       (10,353)      (4,747)       (20,057)
 Finance income                                                              791           1,930         8,143         1,769         4,741
 Loss before taxation                                                        (2,016)       (1,462)       (1,916)       (5,144)       (23,177)
 Tax on loss                                                          6      (704)         (2,189)       (1,483)       (3,616)       (7,274)
 Loss for the period                                                         (2,720)       (3,651)       (3,399)       (8,760)       (30,451)
 Loss for the period attributable to:
 - Owners of the parent                                                      (2,858)       (3,775)       (4,141)       (9,132)       (32,087)
 - Non-controlling interest                                                  138           124           742           372           1,636
                                                                             (2,720)       (3,651)       (3,399)       (8,760)       (30,451)

 Earnings per share
 Basic loss per share (pence)                                         7      (0.40)        (0.54)        (0.57)        (1.32)        (4.60)
 Diluted loss per share (pence)                                       7      (0.40)        (0.54)        (0.57)        (1.32)        (4.60)

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items

 

 

Benchmark Holdings plc

 

Consolidated Statement of Comprehensive Income for the period ended 31 March
2023

 

 

 All figures in £000's                                                     Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)

 Loss for the period                                                       (2,720)       (3,651)       (3,399)       (8,760)       (30,451)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                  (5,973)       9,812         (24,013)      7,201         47,606
 Cash flow hedges - changes in fair value                                  217           3,082         (299)         2,948         2,627
 Cash flow hedges - reclassified to profit or loss                         (179)         63            (292)         178           2,546
 Total comprehensive income for the period                                 (8,655)       9,306         (28,003)      1,567         22,328

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                    (8,295)       8,784         (28,046)      836           20,326
 - Non-controlling interest                                                (360)         522           43            731           2,002
                                                                           (8,655)       9,306         (28,003)      1,567         22,328

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

 

Consolidated Balance Sheet as at 31 March 2023

 

 

                                                                          31 March 2023  31 March 2022  30 September 2022
 All figures in £000's                                             Notes  (unaudited)    (unaudited)    (audited)
 Assets
 Property, plant and equipment                                            76,414         81,568         81,900
 Right-of-use assets                                                      22,365         31,360         27,034
 Intangible assets                                                        215,077        226,912        245,264
 Equity-accounted investees                                               3,136          2,821          3,113
 Other investments                                                        14             15             15
 Biological and agricultural assets                                       20,605         17,089         20,878
 Non-current assets                                                       337,611        359,765        378,204
 Inventories                                                              27,129         22,140         29,813
 Biological and agricultural assets                                       22,550         24,294         25,780
 Trade and other receivables                                              48,433         47,275         56,377
 Cash and cash equivalents                                                38,647         46,294         36,399
 Current assets                                                           136,759        140,003        148,369
 Total assets                                                             474,370        499,768        526,573
 Liabilities
 Trade and other payables                                                 (29,723)       (33,284)       (44,324)
 Loans and borrowings                                              8      (22,115)       (13,546)       (17,091)
 Corporation tax liability                                                (8,413)        (7,733)        (10,211)
 Provisions                                                               (1,574)        (551)          (1,631)
 Current liabilities                                                      (61,825)       (55,114)       (73,257)
 Loans and borrowings                                              8      (82,878)       (114,185)      (93,045)
 Other payables                                                           (6,257)        (936)          (8,996)
 Deferred tax                                                             (24,293)       (27,524)       (27,990)
 Non-current liabilities                                                  (113,428)      (142,645)      (130,031)
 Total liabilities                                                        (175,253)      (197,759)      (203,288)
 Net assets                                                               299,117        302,009        323,285
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     9      739            704            704
 Additional paid-in share capital                                  9      37,924         420,824        420,824
 Capital redemption reserve                                               5              5              5
 Retained earnings                                                        201,962        (162,696)      (185,136)
 Hedging reserve                                                          (1,294)        (2,750)        (703)
 Foreign exchange reserve                                                 54,391         37,307         77,705
 Equity attributable to owners of the parent                              293,727        293,394        313,399
 Non-controlling interest                                                 5,390          8,615          9,886
 Total equity and reserves                                                299,117        302,009        323,285

 

The accompanying notes are an integral part of this consolidated financial
information.

Benchmark Holdings plc

 

Consolidated Statement of Changes in Equity for the period ended 31 March 2023

 

 

                                                          Share     Additional paid-in share capital*      Other      Hedging      Retained     Total attributable       Non-          Total

capital
reserves
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                          £000      £000                                   £000       £000         £000         £000                     £000          £000

 As at 1 October 2022 (audited)                          704       420,824                                77,710     (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                            -         -                                      -          -            (4,141)      (4,141)                  742           (3,399)
 Other comprehensive income/(loss)                       -         -                                      (23,314)   (591)        -            (23,905)                 (699)         (24,604)
 Total comprehensive income/(loss) for the period        -         -                                      (23,314)   (591)        (4,141)      (28,046)                 43            (28,003)
 Contributions by and distributions to owners
 Share issue                                             35        12,985                                 -          -            -            13,020                   -             13,020
 Share issue costs recognised through equity             -         (1,650)                                -          -            -            (1,650)                  -             (1,650)
 Cancellation of part of share premium account (note 9)  -         (394,235)                              -          -            394,235      -                        -             -
 Share-based payment                                     -         -                                      -          -            475          475                      -             475
 Total contributions by and distributions to owners      35        (382,900)                              -          -            394,710      11,845                   -             11,845
 Changes in ownership
 Acquisition of NCI                                      -         -                                      -          -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                    -         -                                      -          -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company           35        (382,900)                              -          -            391,240      8,375                    (4,539)       3,836
 As at 31 March 2023 (unaudited)                         739       37,924                                 54,396     (1,294)      201,963      293,728                  5,390         299,118

 As at 1 October 2021 (audited)                          670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income/(loss)for the period
 Profit/(loss) for the period                            -         -                                      -          -            (9,132)      (9,132)                  372           (8,760)
 Other comprehensive income/(loss)                       -         -                                      6,842      3,126        -            9,968                    359           10,327
 Total comprehensive income/(loss) for the period        -         -                                      6,842      3,126        (9,132)      836                      731           1,567
 Contributions by and distributions to owners
 Share issue                                             34        20,704                                 -          -            -            20,738                   -             20,738
 Share issue costs recognised through equity             -         (562)                                  -          -            -            (562)                    -             (562)
 Share-based payment                                     -         -                                      -          -            667          667                      -             667
 Total contributions by and distributions to owners      34        20,142                                 -          -            667          20,843                   -             20,843
 Changes in ownership
 Total changes in ownership interests                    -         -                                      -          -            -            -                        -             -
 Total transactions with owners of the Company           34        20,142                                 -          -            667          20,843                   -             20,843
 As at 31 March 2022 (unaudited)                         704       420,824                                37,312     (2,750)      (162,696)    293,394                  8,615         302,009

 As at 1 October 2021 (audited)                          670       400,682                                30,470     (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                            -         -                                      -          -            (32,087)     (32,087)                 1,636         (30,451)
 Other comprehensive income/(loss)                       -         -                                      47,240     5,173        -            52,413                   366           52,779
 Total comprehensive income/(loss) for the period        -         -                                      47,240     5,173        (32,087)     20,326                   2,002         22,328
 Contributions by and distributions to owners
 Share issue                                             34        20,704                                 -          -            -            20,738                   -             20,738
 Share issue costs recognised through equity             -         (562)                                  -          -            -            (562)                    -             (562)
 Share-based payment                                     -         -                                      -          -            1,182        1,182                    -             1,182
 Total contributions by and distributions to owners      34        20,142                                 -          -            1,182        21,358                   -             21,358
 Changes in ownership
 Total changes in ownership interests                    -         -                                      -          -            -            -                        -             -
 Total transactions with owners of the Company           34        20,142                                 -          -            1,182        21,358                   -             21,358
 As at 30 September 2022 (audited)                       704       420,824                                77,710     (703)        (185,136)    313,399                  9,886         323,285

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve

Benchmark Holdings plc

 

Consolidated Statement of Cashflows for the period ended 31 March 2023

 

 

                                                                                 31 March 2023  31 March 2022  30 September 2022
                                                                          Notes  (unaudited)    (unaudited)    (audited)
 Cash flows from operating activities
 Loss for the period                                                             (3,399)        (8,760)        (30,451)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment                    4,248          4,187          8,602
 Depreciation and impairment of right-of-use assets                              4,918          5,865          11,295
 Amortisation and impairment of intangible fixed assets                          9,912          8,872          19,161
 Loss on sale of property, plant and equipment                                   (36)           -              (43)
 Finance income                                                                  (320)          (225)          (319)
 Finance costs                                                                   1,715          3,714          18,437
 Increase in fair value of contingent consideration receivable                   -              (909)          (1,203)
 Share of profit/(loss) of equity-accounted investees, net of tax                (55)           528            595
 Foreign exchange losses                                                         (1,104)        841            (3,985)
 Share-based payment expense                                                     475            667            1,182
 Other adjustments for non-cash items                                            -              -              (276)
 Tax charge                                                                      1,482          3,616          7,274
 Decrease/(increase) in trade and other receivables                              6,071          108            (8,511)
 Decrease/(increase) in inventories                                              2,517          (1,610)        (5,406)
 Decrease/(increase) in biological and agricultural assets                       893            (1,635)        (6,099)
 (Decrease)/increase in trade and other payables                                 (13,673)       (10,317)       6,946
 (Decrease)/increase in provisions                                               (13)           (12)           1,058
                                                                                 13,631         4,930          18,257
 Income taxes paid                                                               (4,141)        (2,975)        (7,447)
 Net cash flows generated from operating activities                              9,490          1,955          10,810
 Investing activities
 Acquisition of minority interests in subsidiaries, net of cash acquired  12     (8,009)        -              -
 Purchase of investments                                                         (307)          (48)           (378)
 Receipts from disposal of investments                                           -              -              1,544
 Purchases of property, plant and equipment                                      (3,254)        (5,084)        (10,808)
 Purchase of intangibles                                                         (77)           (1,523)        (205)
 Capitalised research and development costs                                      (197)          -              (1,708)
 Proceeds from sale of fixed assets                                              77             3              220
 Interest received                                                               319            25             119
 Net cash flows used in investing activities                                     (11,448)       (6,627)        (11,216)
 Financing activities
 Proceeds of share issues                                                        13,020         20,782         20,737
 Share-issue costs recognised through equity                                     (1,650)        (607)          (562)
 Proceeds from bank or other borrowings                                          21,393         -              67,939
 Repayment of bank or other borrowings                                           (16,560)       (939)          (74,874)
 Capitalised borrowing costs                                                     (591)          -              -
 Interest and finance charges paid                                               (4,082)        (3,757)        (9,629)
 Repayments of lease liabilities                                                 (4,689)        (4,769)        (10,533)
 Net cash inflow/(outflow) from financing activities                             6,841          10,710         (6,922)
 Net increase/(decrease) in cash and cash equivalents                            4,883          6,038          (7,328)
 Cash and cash equivalents at beginning of period                                36,399         39,460         39,460
 Effect of movements in exchange rate                                            (2,634)        796            4,267
 Cash and cash equivalents at end of period                                      38,648         46,294         36,399

Benchmark Holdings plc

 

Unaudited notes to the quarterly financial statements for the period ended 31
March 2023

 

 

 

1.       Basis of preparation

Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the six months ended 31 March 2023 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').

 

These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .

 

The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the six months ended 31 March 2022. The
comparative figures for the financial year ended 30 September 2022 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 30 November 2022 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not include a reference to any matters to which the
external auditor drew attention by way of emphasis without qualifying their
report, and (iii) did not contain a statement under section 498(2) or (3) of
the Companies Act 2006.

 

Statement of Compliance

 

These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's last annual consolidated financial statements as at and for the year
ended 30 September 2022. These consolidated quarterly financial statements
were approved by the Board of Directors on 23 May 2023.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 31 March 2023 the Group had net assets of £299.1m (30 September 2022:
£323.3m), including cash of £38.6m (30 September 2022: £36.4m) as set out
in the consolidated balance sheet. The Group made a loss for the six months of
£3.4m (year ended 30 September 2022: loss £30.5m).

 

As noted in the Management Report, the business has continued to perform well
on the back of a good year in FY22. All of the business areas have performed
in line with or ahead of management expectations. The Directors have reviewed
forecasts and cash flow projections for a period of at least 12 months
including downside sensitivity assumptions in relation to trading performance
across the Group to assess the impact on the Group's trading and cash flow
forecasts and on the forecast compliance with the covenants included within
the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and demand for artemia feeds in certain territories. Mitigating
measures within the control of management have been identified should they be
required in response to these sensitivities, including reductions in areas of
discretionary spend, tight control over new hires, and deferral of capital
projects.

 

The refinancing exercise which commenced in FY22 was completed in Q1 FY23, so
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
the global economic pressures, caused mainly by the conflict in Eastern
Europe. The Directors are therefore confident that even under all of the above
sensitivity analysis, the Group has sufficient liquidity and resources
throughout the period under review whilst still maintaining adequate headroom
against the borrowing covenants and remain confident that the Group has
adequate resources to continue to meet its liabilities as and when they fall
due within the period of 12 months from the date of approval of these
financial statements. Based on their assessment, the Directors believe it
remains appropriate to prepare the financial statements on a going concern
basis.

 

 

 

2.      Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU or UK-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2022.

 

3.      Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health - the segment provides health products and services to the
global aquaculture market.

3.     Segment information (continued)

 

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

  Segmental Revenue
  All figures in £000's       Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022    FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
   Genetics                   13,042        11,408        34,481        26,603         58,008
   Advanced Nutrition         22,644        22,974        45,324        42,033         80,286
   Health                     8,692         4,916         19,077        10,693         20,135
   Corporate                  1,436         1,406         2,873         2,812          5,120
   Inter-segment sales        (1,447)       (1,471)       (2,893)       (2,894)        (5,272)
   Total                      44,367        39,233        98,862        79,247         158,277

  Segmental Adjusted EBITDA
  All figures in £000's        Q2 2023       Q2 2022      YTD Q2 2023    YTD Q2 2022    FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
   Genetics                   3,420         2,428         5,983         5,691          15,980
   Advanced Nutrition         6,169         7,154         11,466        11,474         19,017
   Health                     2,583         (454)         6,650         93             108
   Corporate                  (1,079)       (703)         (2,039)       (1,408)        (3,924)
   Total                      11,093        8,425         22,060        15,850         31,181

 

Reconciliations of segmental information to IFRS measures

 

   Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
  All figures in £000's                                                  Q2 2023       Q2 2022      YTD Q2 2023    YTD Q2 2022    FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
  Total reportable segment Adjusted EBITDA                              12,172        9,128         24,099        17,258         35,105
  Corporate Adjusted EBITDA                                             (1,079)       (703)         (2,039)       (1,408)        (3,924)
  Adjusted EBITDA                                                       11,093        8,425         22,060        15,850         31,181
  Exceptional - restructuring, disposal and acquisition related items   (1,716)       908           (2,688)       908            16
  Depreciation and impairment                                           (4,551)       (5,557)       (9,166)       (10,052)       (19,897)
  Amortisation and impairment                                           (4,410)       (4,484)       (9,912)       (8,872)        (19,161)
  Net finance costs                                                     (2,432)       (754)         (2,210)       (2,978)        (15,316)
  Loss before taxation                                                  (2,016)       (1,462)       (1,916)       (5,144)        (23,177)

 

 

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.

Disaggregation of revenue

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

 

Sale of goods and provision of services

 

                          3 months ended 31 March 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           11,083      22,635                6,115      -            -                      39,833
  Provision of services   1,957       -                     2,577      -            -                      4,534
  Inter-segment sales     2           9                     -          1,436        (1,447)                -
                          13,042      22,644                8,692      1,436        (1,447)                44,367

                          3 months ended 31 March 2022 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           9,872       22,945                2,594      -            -                      35,411
  Provision of services   1,500       -                     2,322      -            -                      3,822
  Inter-segment sales     36          29                    -          1,406        (1,471)                -
                          11,408      22,974                4,916      1,406        (1,471)                39,233

                          6 months ended 31 March 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           32,204      45,307                13,564     -            -                      91,075
  Provision of services   2,274       -                     5,513      -            -                      7,787
  Inter-segment sales     3           17                    -          2,873        (2,893)                -
                          34,481      45,324                19,077     2,873        (2,893)                98,862

                          6 months ended 31 March 2022 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           24,381      41,993                5,845      -            -                      72,219
  Provision of services   2,180       -                     4,848      -            -                      7,028
  Inter-segment sales     42          40                    -          2,812        (2,894)                -
                          26,603      42,033                10,693     2,812        (2,894)                79,247

 

4.     Revenue (continued)

 

Sale of goods and provision of services (continued)

 

                          12 months ended 30 September 2022 (audited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Sale of goods           53,978      80,191                13,528     -            -                      147,697
  Provision of services   3,973       -                     6,607      -            -                      10,580
  Inter-segment sales     57          95                    -          5,120        (5,272)                -
                          58,008      80,286                20,135     5,120        (5,272)                158,277

 

Primary geographical markets

 

                         3 months ended 31 March 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
   Norway                6,177       252                   6,157      -            -                      12,586
   India                 -           2,822                 -          -            -                      2,822
   Turkey                -           2,528                 -          -            -                      2,528
   Greece                -           2,002                 -          -            -                      2,002
   Faroe Islands         2,224       -                     119        -            -                      2,343
   Ecuador               9           1,832                 -          -            -                      1,841
   United Kingdom        814         8                     -          -            -                      822
   Chile                 1,121       9                     88         -            -                      1,218
  Vietnam                -           2,330                 -          -            -                      2,330
  Rest of Europe         1,680       1,716                 -          -            -                      3,396
  Rest of World          1,015       9,136                 2,328      -            -                      12,479
  Inter-segment sales    2           9                     -          1,436        (1,447)                -
                         13,042      22,644                8,692      1,436        (1,447)                44,367

                         3 months ended 31 March 2022 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
  Norway                 6,115       211                   4,288      -            -                      10,614
  India                  260         3,711                 -          -            -                      3,971
  Turkey                 -           2,238                 -          -            -                      2,238
  Greece                 -           1,832                 -          -            -                      1,832
  Faroe Islands          1,709       5                     147        -            -                      1,861
  Ecuador                -           1,227                 -          -            -                      1,227
  United Kingdom         899         14                    30         -            -                      943
  Chile                  224         5                     150        -            -                      379
  Vietnam                -           3,014                 -          -            -                      3,014
  Rest of Europe         1,590       1,278                 -          -            -                      2,868
  Rest of World          575         9,410                 301        -            -                      10,286
  Inter-segment sales    36          29                    -          1,406        (1,471)                -
                         11,408      22,974                4,916      1,406        (1,471)                39,233

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         6 months ended 31 March 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
   Norway                23,061      342                   14,452     -            -                      37,855
   India                 -           7,025                 -          -            -                      7,025
   Turkey                2           4,732                 -          -            -                      4,734
   Greece                -           4,271                 -          -            -                      4,271
   Faroe Islands         3,319       -                     348        -            -                      3,667
   Ecuador               29          3,572                 -          -            -                      3,601
   United Kingdom        1,551       27                    42         -            -                      1,620
   Chile                 1,133       11                    342        -            -                      1,486
  Vietnam                -           5,025                 -          -            -                      5,025
  Rest of Europe         3,742       3,338                 -          -            -                      7,080
  Rest of World          1,641       16,964                3,893      -            -                      22,498
  Inter-segment sales    3           17                    -          2,873        (2,893)                -
                         34,481      45,324                19,077     2,873        (2,893)                98,862

                         6 months ended 31 March 2022 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
   Norway                15,794      323                   8,956      -            -                      25,073
   India                 400         7,719                 -          -            -                      8,119
   Turkey                -           3,932                 -          -            -                      3,932
   Greece                -           3,471                 -          -            -                      3,471
   Faroe Islands         2,856       28                    118        -            -                      3,002
   Ecuador               -           2,291                 -          -            -                      2,291
   United Kingdom        2,601       6                     277        -            -                      2,884
   Chile                 340         5                     553        -            -                      898
  Vietnam                -           6,009                 -          -            -                      6,009
  Rest of Europe         3,361       2,581                 -          -            -                      5,942
  Rest of World          1,209       15,628                789        -            -                      17,626
  Inter-segment sales    42          40                    -          2,812        (2,894)                -
                         26,603      42,033                10,693     2,812        (2,894)                79,247

 

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         12 months ended 30 September 2022 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total
   Norway                34,666      965                   15,571     -            -                      51,202
   India                 619         12,001                -          -            -                      12,620
   Turkey                -           6,419                 -          -            -                      6,419
   Greece                2           6,197                 -          -            -                      6,199
   Faroe Islands         5,465       9                     587        -            -                      6,061
   Ecuador               18          6,472                 -          -            -                      6,490
   United Kingdom        4,318       93                    199        -            -                      4,610
   Chile                 1,006       15                    871        -            -                      1,892
  Vietnam                -           10,512                -          -            -                      10,512
  Rest of Europe         7,110       4,056                 -          -            -                      11,166
  Rest of World          4,747       33,452                2,907      -            -                      41,106
  Inter-segment sales    57          95                    (0)        5,120        (5,272)                (0)
                         58,008      80,286                20,135     5,120        (5,272)                158,277

 

5.     Exceptional - restructuring, disposal, and acquisition related
items

 

Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 All figures in £000's                Q2 2023       Q2 2022                                       YTD Q2 2023   YTD Q2 2022                                   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
  Exceptional restructuring costs     1,716                             -                         2,688                             -                         1,229
  Income in relation to disposals     -             (908)                                         -             (908)                                         (1,245)
 Total exceptional items              1,716         (908)                                         2,688         (908)                                         (16)

 

Exceptional restructuring costs for the quarter include £1,666,000 (YTD 2023:
£2,553,000; FY 2022: £843,000) of legal and professional costs in relation
to preparing for listing the Group on the Oslo stock exchange, and £50,000
(YTD 2023: £135,000; FY 2022: £276,000) relating to other restructuring
costs.

 

Income in relation to disposals for Q2 2022 and YTD Q2 2022 of £908,000
relate to an increase in the fair value of contingent consideration receivable
following the disposal of Improve International Limited in 2020.  Further to
this, the balance in FY 2022 includes £294,000 of additional contingent
consideration received relating to the disposal of Aquaculture UK in 2020.

 

6.     Taxation

 All figures in £000's                                     Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      997           2,642         2,835         5,007         11,727
 Adjustment in respect of prior periods                    -             -             -             -             (39)
 Total current tax charge                                  997           2,642         2,835         5,007         11,688

 Deferred tax:
 Origination and reversal of temporary differences         (293)         (453)         (1,352)       (1,391)       (4,414)
 Deferred tax movements in respect of prior periods        -             -             -             -             -
 Total deferred tax credit                                 (293)         (453)         (1,352)       (1,391)       (4,414)
                                                                                                     -             -
 Total tax charge                                          704           2,189         1,483         3,616         7,274

 

7.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

 

                                                            Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Loss attributable to equity holders of the parent (£000)   (2,858)       (3,775)       (4,141)       (9,132)       (32,087)
 Weighted average number of shares in issue (thousands)     723,173       703,926       724,505       692,474       698,233
 Basic loss per share (pence)                               (0.40)        (0.54)        (0.57)        (1.32)        (4.60)

 

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 4,312,880 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2022: 6,240,304 and 31 March 2022: 5,184,054). These potential ordinary shares
could dilute earnings/loss per share in the future.

 

8.     Loans and borrowings

 

                             YTD Q2 2023  YTD Q2 2022  FY 2022
 All figures in £000's       (unaudited)  (unaudited)  (audited)
 Non-Current
 2025 750m NOK Loan notes    56,756       -            61,054
 2023 850m NOK Loan notes    -            76,353       -
 Bank borrowings             16,974       18,917       17,226
 Lease liabilities           9,148        18,915       14,765
                             82,878       114,185      93,045
 Current
 Bank borrowings             9,421        1,648        5,569
 Lease liabilities           12,694       11,899       11,522
                             22,115       13,546       17,091
 Total loans and borrowings  104,993      127,732      110,136

 

On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments. The proceeds were used to repay its existing NOK 850m floating rate
listed bond, originally raised in June 2019.  The bond was listed on the Oslo
Stock Exchange during the current period on 12 April 2023.

 

On 21 November 2022, the Group refinanced its USD15m RCF, which was provided
by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured GBP20m RCF
provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk-free reference or IBOR rates
depending on which currency is drawn.

 

On 15 February 2023, the Group drew down €9,000,000 on the GBP20,000 RCF
leaving £12,110,000 undrawn as at 31 March 2023.

 

Additionally, during the period, on 1 November 2022, the Group's Nordea Bank
term loan of NOK 165.6m, which had a term loan of five years ending in
November 2023 and interest rate of 2.5% above three month NIBOR, was
refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms of this facility remain the same.

 

9.     Share capital and additional paid-in share capital

 

                                                    Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid                              £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2022                       703,960,798  704            420,824
 Shares issued through placing and open offer       35,189,350   35             11,335
 Cancellation of part of the share premium account  -            -              (394,235)
 Exercise of share options                          127,321      -              -
 Balance at 31 March 2023                           739,277,469  739            37,924

 

On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £1.7m were in relation to the
share issues and this has been charged to the share premium account (presented
within additional paid-in share capital).

 

The share premium account is used to record the aggregate amount of value of
the premiums paid when the Company's shares are issued/redeemed at a premium.
On 20 March 2023, part of the Company's share premium account was cancelled
following the confirmation of the capital reduction by the High Court of
England and Wales on 14 March 2023 and the subsequent registration of the
court order with the Registrar of Companies. The capital reduction created
additional distributable reserves to the value of £394,235,072.

 

10.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

 

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.

 

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

 

Adjusted Operating Profit is operating profit/loss before exceptional items
and amortisation and impairment of intangible assets excluding development
costs as reconciled below.

 

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.

 

10.  Alternative performance measures and other metrics (continued)

 

Reconciliation of Adjusted Operating Profit to Operating Loss

 

 All figures in £000's                                                             Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Revenue                                                                           44,367        39,233        98,862        79,247        158,277
 Cost of sales                                                                     (19,549)      (19,210)      (49,817)      (39,725)      (75,149)
 Gross profit                                                                      24,818        20,023        49,045        39,522        83,128
 Research and development costs                                                    (1,435)       (1,590)       (2,998)       (3,237)       (6,691)
 Other operating costs                                                             (12,290)      (9,984)       (24,043)      (19,907)      (44,661)
 Depreciation and impairment                                                       (4,551)       (5,557)       (9,166)       (10,052)      (19,897)
 Amortisation of capitalised development costs                                     (610)         (448)         (1,227)       (896)         (2,165)
 Share of loss of equity accounted investees net of tax                            -             (24)          56            (528)         (595)
 Adjusted operating profit                                                         5,932         2,420         11,667        4,902         9,119
 Exceptional - restructuring, disposal and acquisition related items               (1,716)       908           (2,688)       908           16
 Amortisation and impairment of intangible assets excluding development costs      (3,800)       (4,036)       (8,685)       (7,976)       (16,996)
 Operating profit/(loss)                                                           416           (708)         294           (2,166)       (7,861)

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 

 All figures in £000's                                                             Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)

 Loss before taxation                                                              (2,016)       (1,462)       (1,916)       (5,144)       (23,177)
 Exceptional - restructuring, disposal and acquisition related items               1,716         (908)         2,688         (908)         (16)
 Amortisation and impairment of intangible assets excluding development costs      3,800         4,036         8,685         7,976         16,996
 Adjusted profit before tax                                                        3,500         1,666         9,457         1,924         (6,197)

 

Other Metrics

 All figures in £000's                       Q2 2023       Q2 2022       YTD Q2 2023   YTD Q2 2022   FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Total R&D Investment
 Research and development costs              1,435         1,590         2,998         3,237         6,691
 Internal capitalised development costs      144           777           198           1,404         1,708
 Total R&D investment                        1,579         2,367         3,196         4,641         8,399

 

 All figures in £000's                                                    Q2 2023       Q2 2022      YTD Q2 2023    YTD Q2 2022    FY 2022

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                         11,093        8,425         22,060        15,850         31,181
 Exclude fair value movement                                             (1,401)       (1,101)       (247)         (1,005)        (1,595)
 Adjusted EBITDA excluding fair value movement in biological assets      9,692         7,324         21,813        14,845         29,586

 

10.  Alternative performance measures and other metrics (continued)

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

                              31 March 2023
 All figures in £000's        (unaudited)
 Cash and cash equivalents    38,647
 Undrawn bank facility        12,110
                              50,757

 

The undrawn bank facility relates to the RCF facility.  At 31 March 2023,
£7.9m of the RCF was drawn (30 September 2022: £4.0m and 31 March 2022:
£nil), leaving £12.1m undrawn (30 September 2022: £9.4m and 31 March 2022:
£nil).

 

11.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

                                                                     31 March 2023  31 March 2022  30 September 2022
 All figures in £000's                                               (unaudited)    (unaudited)    (audited)
 Cash and cash equivalents                                           38,647         46,294         36,399
 Loans and borrowings (excluding lease liabilities) - current        (9,421)        (1,647)        (5,569)
 Loans and borrowings (excluding lease liabilities) - non-current    (73,730)       (95,270)       (78,280)
 Net debt excluding lease liabilities                                (44,504)       (50,623)       (47,450)
 Lease liabilities - current                                         (12,694)       (11,899)       (11,522)
 Lease liabilities - non-current                                     (9,148)        (18,915)       (14,765)
 Net debt                                                            (66,346)       (81,437)       (73,737)

 

12.   Purchase of minority interests in subsidiary companies

On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000,000.
Following this acquisition, Benchmark Genetics Limited, a subsidiary of
Benchmark Holdings PLC, now owns 100% of the share capital of Benchmark
Genetics Iceland HF.

On 6 February 2023, the Group exercised the put/call option in place to
purchase the final 20% of Benchmark Genetics USA Inc for 1 NOK.  Following
this acquisition, Benchmark Genetics Limited, a subsidiary of Benchmark
Holdings PLC, now owns 100% of the share capital of Benchmark Genetics USA
Inc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IR SEIESEEDSEII

Recent news on Benchmark Holdings

See all news